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Hormone replacement therapy
To the Editor: The Women’s Health Initiative (WHI) trial1
constitutes the subject of an editorial in the September 2002
SAMJ2 and deserves comment.
The following quotes from Professor Leon Speroff3 put the
results in perspective: 
• ‘It is not without some trepidation that I challenge the image
of WHI as an unflawed study.’
• ‘Quoting Trudy Bush “it takes many views to come close to
the truth”.’
• ‘Combined HRT is unlikely to benefit the heart’ (WHI). ‘The
results do not justify a definitive conclusion’ (Speroff).
• ‘In regard to cardiovascular disease: this may not be a pure
primary prevention trial.’
• ‘Contrary to the impression reported in the media the
statistical calculations for coronary heart disease, stroke and
breast cancer are not overwhelming in their strength.’
• ‘I don’t believe we should disregard a large body of biologic
(including the monkey experiments in Tom Clarkson’s
group) and epidemiological evidence and make decisions
solely based upon the WHI.’
• ‘Hopefully with time, a more objective and less emotional
understanding of post menopausal hormone therapy will be
reached.’
Gynaecologically, the trial is unsound. In 1993 unopposed
oestrogens were prescribed to 331 women with a uterus, and
progestin was added in 1996! Also in 1993, about 9% of the trial
subjects were reputed to be either past or current users of
unopposed oestrogens and to have a uterus!  
The hazard ration (HR) of venous thromboembolic disease is
the only clinical outcome (Table II in the WHI study1 to fulfil
the statistical criteria of increased risk of disease (the HR must
be in excess of 2.00) 4 and a statistically significant adjusted 95%
confidence interval (CI). All the rest with HRs between 1.00
and 2.00 represent an increased risk but weak association only5
and are not statistically significant because the adjusted 95% CI
crosses one. Similarly, colerectal cancer, hip and vertebral
fractures are also not statistically significant.
The ratio of disease outcome (Table I) shows impressive
increases from year 4 to 5 and even larger reductions from year
5 to 6 and later. The significance of this unsustained rise in year
5 is uncertain.
The changes in the disease outcome results correlate more
closely with the placebo outcome inversely than with the
treatment incidence (Table I).
The year 6 and later drop is discounted by the writers: ‘the
narrowing of the difference by year 6 is because HR estimates
tend to be unstable beyond 6 years after randomisation’. No
references are given. The planned duration of the trial was 8.5
years. Over 25% of subjects had used HRT before the start of
the trial!
If Table IV in the WHI study is analysed 2-yearly, no major
impact is noted in the last 2 years (Table II). This reduces the
risk of 1-year bias considering the small number of events
involved.
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Table I. Adapted from the WHI study Table IV1
Changes Changes
from from year
6 and year 4 5 to 6 and
Year 1 2 3 4 5 later to 5 later
Ratio of
disease outcome
CHD 1.78 1.15 1.06 0.99 2.38 0.78 +1.39 -1.60
Breast cancer 0.62 0.83 1.16 1.73 2.64 1.12 +0.91 -1.52
VTE 3.60 2.26 1.67 1.84 2.49 0.90 +0.65 -1.59
Stroke 0.95 1.72 1.79 1.70 1.87 0.66 +0.17 -1.21
TREATMENT
CHD 0.51 0.43 0.24 0.32 0.39 0.33 +0.07 -0.06
Breast cancer 0.12 0.31 0.34 0.50 0.57 0.53 +0.07 -0.04
VTE 0.58 0.31 0.25 0.34 0.27 0.23 -0.07 -0.04
Stroke 0.20 0.32 0.36 0.32 0.39 0.33 +0.07 -0.06
PLACEBO
CHD 0.29 0.38 0.23 0.32 0.16 0.42 -0.16 +0.26
Breast cancer 0.21 0.38 0.29 0.29 0.22 0.47 -0.07 +0.25
VTE 0.16 0.14 0.15 0.19 0.11 0.26 -0.08 +0.15
Stroke 0.21 0.19 0.20 0.19 0.14 0.35 -0.05 +0.21
CHD = coronary heart disease;  VTE = venous thromboembolism
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Other statistical problems include previous HRT use and a
drop in rate for HRT of 6.2% and placebo of 10.7%. Drop-out
rates for HRT (42%) and placebo (38%) exceeded design
projection particularly early on. Does this allow the trial to
retain the validity of a randomised trial?
With so few events it also decreases the power of the study
from 90% to 70% to detect a 50% change in risk. The long-term
benefits are difficult to assess using the intention-to-treat
method of analysis with its high early drop-out rates.
The lack of cardiovascular benefit is due to the high
percentage of women at high risk of events. Biological evidence
shows that the action of oestrogens is blunted in the presence
of atherosclerosis and hypertension. Coronary artery
atherosclerosis is present in 25% of women aged 55 years and
above.6
The editorial’s two suggestions, viz. that the trial preparation
not be used for long-term disease problems (although the
authors state that there are currently no large randomised
clinical trials on other preparations or routes), and that
utilisation be limited to 4 years, need explanation. Neither
statement is statistically justified on the WHI results, especially
when the HERS trial7 on cardiovascular health does not
confirm the 4-year limit, showing increased risks for the first
year only. A modest increase in the relative risk of venous
thromboembolism mainly in the first years with a decreasing
risk has been shown in case-controlled studies. 8 The possibility
of an increased incidence of breast cancer has long been known
and is probably promotion of an existing breast cancer, which
possibly improves survival rate.
What is required are trials on various combinations and
routes against each other as well as placebo. Would drug firms
allow this? For cardiovascular protection 45 - 55-year-old
women (within 5 years of the menopause) who are
cardiovascularly healthy would be needed to assess long-term
results.
As important are indications and contraindications.
Medication of any sort should only be prescribed if there is an
absolute indication or an informed request.
Before starting and during treatment, investigation should at
least include baseline and yearly mammograms. A
haematological opinion is required for high-risk women or
women with a past or family history of venous
thromboembolism while combined oral contraceptives used for
2 years or more will probably exclude an increased risk. Full
cardiac evaluation is necessary, possibly with a cardiologist’s
opinion if the woman is over 55. Baseline cholesterol should be
measured, and if the woman is on oral HRT triglycerides
should be repeated at 6 months and 1 year. Blood pressure
should be checked 2 - 4 weeks after commencement of
treatment. If the patient is over 55 with cardiovascular risk,
baseline lipoprotein (a), sensitive c-reactive protein (CRP), and
homocysteine levels should be assessed, and if the patient is
hypertensive, prothrombin variant estimations must be done.
Incremental changes from baseline CRP and interleukin 6
(IL6) independently predict future cardiac events in women
from the WHI study irrespective of HRT status and show a
two-fold increase in risk. Use or non-use of HRT has less
importance as a predictor of cardiovascular risk than baseline
levels of CRP.9
Additional reading on the WHI trial 10-14 is suggested. It
should be noted that 5 of the 10 experts who formulated the
North American Menopause Society Consensus report14 were
WHI investigators., An editorial entitled ‘The end of wisdom’ 15
concludes: ‘The closure of this trial is a sad loss for women and
the future health of our daughters. We have let them down.’
R LCheifitz
Christiaan Barnard Memorial Hospital
Cape Town
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Table II. Table IV in the WHI trial analysed 2-yearly 1
Years 1 and 2 Years 3 and 4 Years 5 and 6
average year average year average year
Ratio of
outcome
CHD 1.40 1.02 1.24 
Breast cancer 0.73 1.52 1.60 
VTE 2.97 1.74 1.35
Stroke 1.30 1.74 1.47
